HLB Life Science to expand pipelines after pyrotinib trial success

HLB Life Science, which owns rights to market Jiangsu Hengrui Medicine’s anticancer drug pyrotinib in Korea, said it would expand new pipelines on the back of the recent success of a phase 3 pyrotinib trial.

Jiangsu Hengrui announced that the phase 3 clinical trial of pyrotinib met the primary endpoint as the first-line treatment for breast cancer.

HLB Life Science seeks to expand pipelines as pyrotinib, in combination with trastzumab and docetaxel, reached the primary endpoint in a phase 3 breast cancer study.

According to Jiangsu Hengrui, the phase 3 study of pyrotinib in combination with trastuzumab and docetaxel showed a statistically significant improvement in progression-free survival (PFS) on 590 patients with HER2 positive breast cancer.

In China, pyrotinib sales have been growing rapidly since it won Chinese approval in 2020 as a second-line treatment for breast cancer.

Should it be approved as the first-line treatment, pyrotinib will become more marketable, HLB Life Science said.

The Chinese drugmaker plans to disclose the full results of the phase 3 study at a cancer society’s meeting.

HLB Life Science signed an exclusive licensing agreement with Jiangsu Hengrui for pyrotinib in September 2020.

In December 2020, HLB Life Science received the local approval for a phase 3 clinical trial to treat non-small cell lung cancer (NSCLC).

On July 29, the company submitted a plan for a phase 3 bridging trial of pyrotinib as the third-line treatment for breast cancer.

A bridging trial is a study of a drug authorized in other countries on Koreans to assess the efficacy and safety in different ethnicities.

Back to top button